Evolus

98 articles about Evolus

• Evolus Reports Second Quarter 2022 Results and Provides Business Update

  8/2/2022

  Evolus, Inc.today reported financial results for the second quarter ended June 30, 2022 and provided a business update.

• Evolus to Report Second Quarter 2022 Results and Provide Business Update

  7/19/2022

  Evolus to Report Second Quarter 2022 Results and Provide Business Update.

• Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

  7/12/2022

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has completed patient enrollment in its clinical study evaluating an “extra-strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and the first and only neurotoxin dedicated exclusively to aesthetics.

• Peer-Reviewed Post Hoc Analysis Shows Jeuveau® is Highly Effective for Millennials by All Measures and at All Time Points Assessed

  6/2/2022

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that Dermatologic Surgery published a new post hoc analysis of its Phase III studies comparing millennial patients to non-millennials.

• Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States

  5/18/2022

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, celebrates the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau®, the first and only neurotoxin dedicated exclusively to aesthetics.

• Evolus to Participate in the H.C. Wainwright Global Investment Conference

  5/11/2022

  Evolus, Inc. announced that members of its management team will be participating in the H.C. Wainwright Global Investment Conference.

• Evolus Reports First Quarter 2022 Results and Provides Business Update

  5/10/2022

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results for the first quarter ended March 31, 2022 and provided a business update.

• Evolus to Report First Quarter 2022 Results and Provide Business Update

  4/26/2022

  Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that it will report its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022, after the U.S. financial markets close.

• Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

  3/31/2022

  Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau.

• Evolus Reports Fourth Quarter and Full-Year 2021 Results and Provides Business Update

  3/3/2022

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a business update.

• Evolus Announces Retirement of Chief Financial Officer Lauren Silvernail

  3/3/2022

  Evolus, Inc. announced that after nearly four years with the company, Lauren Silvernail will retire from her position as Chief Financial Officer and Executive Vice President of Corporate Development effective May 31, 2022.

• Evolus Names Christos Monovoukas Senior Vice President of Corporate Development

  3/1/2022

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, has appointed Christos Monovoukas as Senior Vice President, Corporate Development, effective February 28, 2022.

• Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva®

  2/8/2022

  Evolus Receives Acceptance of Submission in Australia, a Pivotal Step in Approval Process for Nuceiva ® .

• Evolus to Participate in the Virtual 11th Annual SVB Leerink Global Healthcare Conference

  2/2/2022

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that members of its management team will be participating in the Virtual 11th Annual SVB Leerink Global Healthcare Conference.

• Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Net Revenue and Provides 2022 Guidance

  1/26/2022

  Evolus, Inc. today announced its preliminary, unaudited net revenue and cash position as of and for the fourth quarter and full-year ended December 31, 2021.

• Evolus Announces Participation in November Investment Conferences

  11/9/2021

  Evolus, Inc. today announced that members of its management team will be participating in two investment conferences in November.

• Evolus Reports Third Quarter 2021 Results and Provides Business Update

  11/2/2021

  Evolus, Inc. today reported financial results for the third quarter ended September 30, 2021.

• Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration

  11/2/2021

  Evolus, Inc. today announced that it has initiated a clinical program to study an “extra strength” dose for extended duration of Jeuveau® (prabotulinumtoxinA-xvfs), its flagship neurotoxin product and first and only neurotoxin dedicated exclusively to aesthetics.

• Evolus Announces Appointment of Jessica Novak as Senior Vice President, Human Resources

  11/1/2021

  Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced that Jessica Novak, SPHR has joined the company as Senior Vice President, Human Resources where she will oversee global efforts to expand, retain and develop an entrepreneurial team bringing innovative products and marketing solutions to the aesthetics industry.

• Evolus to Report Third Quarter 2021 Results and Provide Business Update

  10/22/2021

  Evolus, Inc. today announced that it will report its third quarter 2021 financial results and provide a business update on Tuesday, November 2, 2021, prior to the open of the U.S. financial markets.